Clinical Trials — Respiratory

Draft review set — pulmonary disease — idiopathic pulmonary fibrosis, neonatal ventilation, pneumonia, and lung-nodule diagnosis. Each card leads with the engine's verdict; open any to read the full report before publishing.

Randomized clinical trials in pulmonary disease — idiopathic pulmonary fibrosis, neonatal ventilation, pneumonia, and lung-nodule diagnosis, from NEJM · Lancet · Nature Medicine · BMJ (2024–2026) — reviewed by the Αlpha¹ Rigor Review engine for rigor & reproducibility.

1Reviewed

1Pass

0Warn

0Critical

Sort

Interventional0/6Action Items · Critical / High

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, Zhao L, Dai J, Ding Y, Fang H, Li H, Liu H, Luo F, Meng Y, Pan P, Xiang P, Xiao Z, Rao S, Satler C, Liu S, Lv Y, Zhao H, Chen S, Cui H, Korzinkin M, Gennert D, Zhavoronkov A.

PASSScore 93

Conclusions

10 supported · 2 partial of 12

8 Rigor Dimensions

8 of 8 pass

Verified

6/6 links livestats consistentregistered

3 Αlpha¹ Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Alpha1 corpus · verify findings

Read paperDOI Open record

Share this gallery with your network

Post on X Share on LinkedIn Share via Email

How to read this.The engine surfaces specific, verifiable rigor problems — it does notpredict retractions, and a “pass” is not a guarantee of soundness. Papers are analyzed on their published full text with any retraction notice removed, so detection is content-based. Real-world outcome labels (retracted, landmark) are curator-assigned from the public record; the verdict and every surfaced problem are the engine’s own. These are selected examples.